GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SynCore Biotechnology Co 4192.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

16.55

+4.75%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SynCore Biotechnology Co

Its shares trade on Taipei Exchange under the ticker 4192.TWO. It has been listed since 29 August 2013. In the fiscal year to 31 December 2025, it reported revenue of TWD 27.0m and a net loss of TWD 45.8m. At that date it held total assets of TWD 255.7m and shareholders' equity of TWD 245.6m.

SynCore Biotechnology Co., Ltd. engages in the research and development of new drugs and integration of technology. The company is headquartered in Dongshan, Yilan. The company went IPO on 2013-08-29. The firm's main product is SB03 Veregen. The firm is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The firm distributes its products mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Aug 2013
Employees
50

Leadership

Pay as last reported

  • Mr. Yi-Ta LeeVice Chairman of the Board, since 2008
  • Mr. Chih-Wen LeeChairman of the Board, since 2008
  • Mr. Chia-Hao LiangSenior Manager of Finance & Accounting, Corporate Governance Officer
  • Mr. Hui-Hung WangGeneral Manager
  • Mr. Wen-Hsin HuangDeputy General Manager-Drug Development Department Division
  • Ms. Fern-Fang LinDeputy General Manager-EndoTAG Clinical Development Project
  • Mr. Charn-Jung ChangGeneral Manager-Ophthalmology Project
  • Peishan ChenHead of Accounting
  • Mr. Yu-Liang PaiDirector
  • Ms. Yan-Chiu WuDirector
  • Ms. Hui-Hwa YangDirector
  • Jinjian ZhangDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SB03 Veregen is a key product for domestic market distribution.
  • SB01 injection and oral anticancer drugs are in clinical trials.
  • 50 full-time employees support R&D and technology integration.

Weaknesses

  • Dongshan, Yilan headquarters limits international expansion.
  • Limited domestic market distribution for SB03 Veregen.
  • Only 50 employees restrict R&D scale and speed.

Opportunities

  • SB01 anticancer drugs could expand into international markets.
  • Clinical trials for SB01 may lead to new drug approvals.
  • Growth in Health Care sector offers new market potential.

Threats

  • Competition from other pharmaceutical companies in TW.
  • Regulatory changes in Health Care industry may affect operations.
  • Dependence on domestic market limits global revenue growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.